Last reviewed · How we verify
Intraduodenal denatonium benzoate
Denatonium benzoate is a bitter-tasting compound administered intraduodenally that triggers taste receptors to elicit a protective reflex and modify gastrointestinal function.
Denatonium benzoate is a bitter-tasting compound administered intraduodenally that triggers taste receptors to elicit a protective reflex and modify gastrointestinal function. Used for Dumping syndrome (post-bariatric surgery or post-gastrectomy).
At a glance
| Generic name | Intraduodenal denatonium benzoate |
|---|---|
| Also known as | IG DB |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Bitter taste receptor agonist |
| Target | Bitter taste receptors (T2Rs), particularly TAS2R family members |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Denatonium benzoate is one of the most bitter substances known and activates bitter taste receptors (T2Rs) in the duodenum when delivered directly into the small intestine. This activation triggers vagal afferent signaling and local enteric nervous system responses that modulate gastric emptying, intestinal motility, and potentially nutrient absorption. The bitter taste reflex is thought to provide a protective mechanism against ingestion of potentially toxic substances.
Approved indications
- Dumping syndrome (post-bariatric surgery or post-gastrectomy)
Common side effects
- Bitter taste sensation
- Gastrointestinal discomfort
- Nausea
Key clinical trials
- IG vs ID Bitter Administration (PHASE4)
- The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: